You are here

Bioiberica spotlights the power of partnership at CPhI 2021

15 Nov 2021
Bioiberica

Visit stand 18K20 to discover how Bioiberica’s technical, market and regulatory insights, and vertically integrated supply chain can help manufacturers deliver the health solutions of tomorrow.

Barcelona, 4 November, 2021 – Bioiberica, a leading heparin manufacturer and world reference in the identification, extraction and development of animal-derived active pharmaceutical ingredients (API) with more than 45 years of experience, is set to make its return to CPhI Worldwide next month. The company will be at stand 18K20 to highlight how its established portfolio of pharmaceutical APIs, alongside its vertically integrated supply chain can support brands in the development of innovative solutions for today’s most pressing health challenges.

On stand, experts from Bioiberica’s Heparin Science business unit will be available to discuss the latest market developments and changing regulatory environment impacting the market for heparin – most commonly used as an anti-coagulant drug that saves more than 100 million lives globally, every year.

Luis Solera, CEO at Bioiberica, comments: “Heparin is where it all began and since then, we’ve come a long way – discovering and developing breakthrough biomolecules of animal origin that encompass multiple health areas. Today, we aspire to be more than just an ingredients supplier – providing the support required to overcome the most pertinent challenges facing the pharmaceutical industry.”

Joan Bassa Camps, Business Units Director – Heparin Science, Animal Nutrition and Plant Health, adds: “Everything we do at Bioiberica, is with the aim of being a trusted partner to our customers – many of which we connect with at shows, like CPhI. The partnerships we’ve developed as a result are collaborative and personalised by tailoring our expertise to meet their specific needs. Whether that’s meeting the highest quality and safety standards, ensuring regulatory compliance, or helping them to enhance their traceability and sustainability credentials – all in a constantly evolving landscape – we’re here every step of the way.”

In addition, Bioiberica’s Healthcare team will be showcasing its established range of APIs – Glucosamine and Chondroitin Sulfate – alongside the newest addition to its offering – Thyroid. A natural origin ingredient, Bioiberica’s Thyroid API – also known as natural desiccated thyroid (NDT) – is the result of a strategic collaboration focused on supporting innovation in endocrinology.

Antonio Vendrell, Business Unit Director – Healthcare, adds: “We’re on a mission to meet like-minded businesses who are passionate about improving people’s health – and CPhI provides us with the perfect platform to do this. We’re proactively seeking strategic partnerships with forward-thinking companies looking to kickstart their next advancement and explore how our combined knowledge can bring new and innovative solutions to the healthcare market. Whether it’s developing new APIs, including the development of analytical methods to characterise complex molecules, providing pilot manufacturing or scale-up services, we have a vast range of experience and expertise that can help pharmaceutical companies realise health solutions that have the power to transform lives.”

Bioiberica will also present its flagship branded ingredients at the event for the first time – Collavant n2 native type II collagen and Mobilee® - a hyaluronic acid matrix ingredient.

 

Bioiberica will be on stand 18K20 throughout CPhI 2021.

Related News

23 Jan 2024
Bioiberica

On a planet where natural resources are limited and there is increasing concern for the environment, the circular economy has emerged as an innovative and sustainable solution.

16 Oct 2023
Bioiberica

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023
Bioiberica

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs

Bioiberica